

# **INFORMATION DISCLOSURE STATEMENT BY APPLICANT** ( Not for submission under 37 CFR 1.99)

Application Number	10743563
Filing Date	2003-12-22
First Named Inventor	Jean-Damien Charrier
Art Unit	1625
Examiner Name	Davis, Zinna Northington
Attorney Docket Number	VPI/02-131 US

## **U.S. PATENTS**

Examiner Initial*	Cite No	Patent Number	Kind Code <sup>1</sup>	Issue Date	Name of Patentee or Applicant of cited Document	Pages, Columns, Lines where Relevant Passages or Relevant Figures Appear
	1					

If you wish to add additional U.S. Patent citation information please click the Add button.

## **U.S. PATENT APPLICATION PUBLICATIONS**

Examiner Initial*	Cite No	Publication Number	Kind Code <sup>1</sup>	Publication Date	Name of Patentee or Applicant of cited Document	Pages, Columns, Lines where Relevant Passages or Relevant Figures Appear
	1					

If you wish to add additional U.S. Published Application citation information please click the Add button.

## **FOREIGN PATENT DOCUMENTS**

Examiner Initial*	Cite No	Foreign Document Number <sup>3</sup>	Country Code <sup>2</sup>	Kind Code <sup>4</sup>	Publication Date	Name of Patentee or Applicant of cited Document	Pages, Columns, Lines where Relevant Passages or Relevant Figures Appear	T <sup>5</sup>
	1	2003042169	WO	A2	2003-05-22	Vertex Pharmaceuticals Incorporated		<input type="checkbox"/>
	2	9603982	WO	A1	1996-02-15	Sanofi Winthrop, Inc.		<input type="checkbox"/>

If you wish to add additional Foreign Patent Document citation information please click the Add button

## **NON-PATENT LITERATURE DOCUMENTS**

**INFORMATION DISCLOSURE  
STATEMENT BY APPLICANT**  
( Not for submission under 37 CFR 1.99)

Application Number	10743563
Filing Date	2003-12-22
First Named Inventor	Jean-Damien Charrier
Art Unit	1625
Examiner Name	Davis, Zinna Northington
Attorney Docket Number	VPI/02-131 US

Examiner Initials*	Cite No	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc), date, pages(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>5</sup>
	1	Pierre Golstein, "Cell death in us and others", Science, 281(5381), 1283, (1998).	<input type="checkbox"/>
	2	Ellis et al., "Mechanisms and functions of cell death", Annual review cell biology", 7, 663, (1991).	<input type="checkbox"/>
	3	Nancy A. Thornberry, "Key mediators of apoptosis", Chemical Biology, 5, R97-R103, (1998).	<input type="checkbox"/>
	4	Hiroiyuki Yaoita et al., "Attenuation of ischemia/reperfusion injury in rats by a caspase inhibitor", Circulation, 97, 276-281 (1998)	<input type="checkbox"/>
	5	M. Endres et al., "Attenuation of delayed neuronal death after mild focal ischemia in mice by inhibition of the caspase family", Journal of Cerebral Blood Flow and Metabolism, 18, 238-247, (1998).	<input type="checkbox"/>
	6	Yu Cheng et al., "Caspase inhibitor affords neuroprotection with delayed administration in a rat model of neonatal hypoxic-ischemic brain injury", Journal of Clinical Investigation, 101, 1992-1999 (1998).	<input type="checkbox"/>
	7	Alexander G. Yakovlev et al., "Activation of CPP32-like caspases contributes to neuronal apoptosis and neurological dysfunction after traumatic brain injury", The Journal of Neuroscience, 17, 7415-7424, (1997).	<input type="checkbox"/>
	8	Ivan Rodriguez et al., "Systemic injection of a tripeptide inhibits the intracellular activation of CPP32-like proteases in vivo and fully protects mice against fas-mediated fulminant liver destruction and death", Journal of Experimental Medicine, 184, 2067-2072, (1996).	<input type="checkbox"/>
	9	Grobmyer et al., "Peptidomimetic fluoromethylketone rescues mice from lethal endotoxic shock [In Process Citation]", 5, 585, (1999).	<input type="checkbox"/>
	10	JJ Plattner et al., "Obstacles to Drug Development from Peptide Leads", Drug Discovery Technologies, 93-126, (1990).	<input type="checkbox"/>

# INFORMATION DISCLOSURE STATEMENT BY APPLICANT

( Not for submission under 37 CFR 1.99)

Application Number	10743563
Filing Date	2003-12-22
First Named Inventor	Jean-Damien Charrier
Art Unit	1625
Examiner Name	Davis, Zinna Northington
Attorney Docket Number	VPI/02-131 US

11	Keith Wilson et al., "Structure and mechanism of interleukin-1 $\beta$ converting enzyme", 370, 270-275, (1994).	<input type="checkbox"/>
12	Lazebnik et al., "Cleavage of poly(ADP-ribose) polymerase by a proteinase with properties like ICE", Nature, 371, 346-347, (1994).	<input type="checkbox"/>
13	Nigel H. Greig et al., "Physicochemical and pharmacokinetic parameters of seven lipophilic chlorambucil esters designed for brain penetration", Cancer Chemotherapy, 25, 311-319, (1990).	<input type="checkbox"/>
14	Shanaz M. Tejani-Butt et al., "Evaluation of mono-and dibenzoyl esters of dopamine as potential pro-drugs for dopamine in the central nervous system", Arch. Pharmacology, 338(5), 497-503, (1988).	<input type="checkbox"/>
15	Katalin Prokai-Tatrai et al., "Brain-targeted delivery of a leucine-enkephalin analogue by retrometabolic design", J. Med. Chem., 39, 4775-4782, (1996).	<input type="checkbox"/>
16	Toyoaki Ishikura et al., "Drug delivery to the brain. DOPA prodrugs based on a ring-closure reaction to quaternary thiazolium compounds", Int. J. Pharmaceutics, 116, 51-63, (1995).	<input type="checkbox"/>
17	Francesco Paolo Bonina, et al., "Synthesis, stability, and pharmacological evaluation of nipecotic acid prodrugs", J. Pharm. Sci., 88(5), 561-567, (1999).	<input type="checkbox"/>
18	G. Battaglia et al., "Systemically administered d-glucose conjugates of 7-chlorokynurenic acid are centrally available and exert anticonvulsant activity in rodents" Brain Res., 860, 149-156, (2000).	<input type="checkbox"/>
19	Josep M. Caba et al., "Solid-phase total synthesis of trunkamide A", J. Org. Chem., 66, 7568-7574, (2001).	<input type="checkbox"/>
20	Gabriele Schierle et al., "Caspase inhibition reduces apoptosis and increases survival of nigral transplants", Nature Medicine, 5, 97-100, (1999).	<input type="checkbox"/>
21	Anderson, "Prodrugs for Improved CNS Delivery", Advanced Drug Deliver Reviews, 19, 171-202, (1996).	<input type="checkbox"/>

**INFORMATION DISCLOSURE  
STATEMENT BY APPLICANT**  
( Not for submission under 37 CFR 1.99)

Application Number	10743563
Filing Date	2003-12-22
First Named Inventor	Jean-Damien Charrier
Art Unit	1625
Examiner Name	Davis, Zinna Northington
Attorney Docket Number	VPI/02-131 US

If you wish to add additional non-patent literature document citation information please click the Add button

**EXAMINER SIGNATURE**

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through a citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> See Kind Codes of USPTO Patent Documents at [www.USPTO.GOV](http://www.USPTO.GOV) or MPEP 901.04. <sup>2</sup> Enter office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>3</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>4</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. <sup>5</sup> Applicant is to place a check mark here if English language translation is attached.